Background: Studies comparing prognosis of breast cancer (BC) patients with and without locoregional recurrence (LR) present conflicting results. We aimed to improve our understanding of the impact of LR on prognosis by examining a large cohort of patients treated at Guy's and St Thomas' NHS Foundation Trust.

Methods: Risk factors associated with BC-specific death were investigated using Cox proportional hazards regression in 5199 women diagnosed between 1975 and 2007. Breast cancer-specific death following LR was assessed with Poisson regression.

Results: Overall, 552 women (11%) developed LR, with a median follow-up time of 4.28 years. Known factors associated with BC-specific death (tumour stage, grade, and nodal status) were of significance in our data. Women with a shorter disease-free interval had a worse prognosis. For instance, the HR for BC-specific death among women undergoing mastectomy with an LR 0.5-1 year after diagnosis of their primary tumour was 6.67 (95% CI: 3.71-11.99), when compared with women who did not experience LR.

Conclusions: It often remains difficult to distinguish between a genuine LR and a new primary. The HRs for risk of BC-specific death following a second lesion suggest that they may act as a marker of systemic disease, large tumour burden, or depleted host defence. The clinically highly relevant impairment in prognosis calls for further research into the underlying mechanisms. We showed that for at least 15 years of follow-up, the prognosis in women following the occurrence of an LR may benefit from careful diagnostic and therapeutic management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716532PMC
http://dx.doi.org/10.1038/bjc.2015.314DOI Listing

Publication Analysis

Top Keywords

bc-specific death
16
breast cancer
8
factors associated
8
associated bc-specific
8
women
6
prognosis
5
death
5
progression breast
4
cancer locoregional
4
locoregional ipsilateral
4

Similar Publications

Purpose: The COVID-19 pandemic created significant disruptions in the diagnosis and treatment of breast cancer (BC). Several public health measures were taken with limited evidence on their potential impact. In this observational study, we sought to compare the incidence of BC, treatment patterns, and mortality during 2020 versus 2018 and 2019.

View Article and Find Full Text PDF
Article Synopsis
  • * The incidence of this breast cancer type rose from 70 to 113 per 100,000 women over the 29 years, with improvements in survival rates over time due to advancements in treatment methods.
  • * Women diagnosed between 2015-2019 had a significantly lower risk of death compared to those diagnosed in the early '90s, highlighting the effectiveness of modern therapies like endocrine treatment in enhancing patient outcomes.
View Article and Find Full Text PDF

Objective: To report real-world outcomes for high-risk non-muscle-invasive bladder cancer (HRNMIBC), including bacillus Calmette-Guérin (BCG) and radical cystectomy (RC), as randomised comparisons of these have not been possible.

Methods: We detail consecutive participants screened for the BRAVO randomised controlled trial comparing RC with BCG (International Standard Randomised Controlled Trial Number [ISRCTN]12509361). Patients were prospectively registered and case-note review used for outcomes.

View Article and Find Full Text PDF

Background And Purpose: Bladder cancer (BC) is a common malignancy in the Western World with men being diagnosed almost four times as often as women. The etiology of bladder cancer may involve sex hormones. Prostate cancer (PCa) patients treated with chemical castration, such as androgen deprivation therapy, or surgical castration, may therefore have a lower risk of developing bladder cancer.

View Article and Find Full Text PDF
Article Synopsis
  • This study analyzes breast cancer-specific survival (BCSS) in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) patients, focusing on changes after the introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in 2015.
  • Researchers used SEER registry data from 11,467 HR+/HER2- mBC patients, finding a 10% reduction in risk of BC-specific death for those diagnosed post-2015 compared to those diagnosed pre-2015, indicating improved survival due to CDK4/6i.
  • In contrast, no significant improvements in BC
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!